IP Library Granted Patent US 12678422
Granted Patent B2
US 12678422 · App. 17/862,117 · Granted Jul 14, 2026

Sulcardine salts

Inventors: Suzanne J. Romano (Carlsbad, CA); Hayley Ann Reece (Dalkeith, GB); Joseph Edward Gordon Benson (Edinburgh, GB); Sarah Collins (Edinburgh, GB); Gary T. Elliott (San Diego, CA); Mireille Gillings (San Diego, CA); Robert Goodenow (San Diego, CA); Curtis Tyree (San Diego, CA)
Assignee: HUYABIO International, LLC
A61K31/4025C07D295/135C07D403/10C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678422
App. No.
17/862,117
Granted
Jul 14, 2026
Kind
B2
Abstract

Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.

Claims (12)

1 . A solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 12.3, 13.0, and 17.8° 2θ.

2 . The solid form of claim 1 , wherein the XRPD pattern further comprises peaks at approximately 13.9, 17.4, and 23.9° 2θ.

3 . The solid form of claim 2 , wherein the XRPD pattern further comprises peaks at approximately 20.3 and 21.9° 2θ.

4 . The solid form of claim 1 , characterized by an XRPD pattern that matches the XRPD pattern presented in FIG. 17 .

5 . A solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 13.5, 19.6, and 20.6° 2θ.

6 . The solid form of claim 5 , wherein the XRPD pattern further comprises peaks at approximately 10.1, 11.8, and 16.4° 2θ.

7 . The solid form of claim 6 , wherein the XRPD pattern further comprises peaks at approximately 17.8, 19.4, and 25.5° 2θ.

8 . The solid form of claim 5 , characterized by an XRPD pattern that matches the XRPD pattern presented in FIG. 17 A .

9 . A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 12.3, 13.0, and 17.8° 2θ.

10 . The pharmaceutical composition of claim 9 , further comprising a capsule.

11 . A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 13.5, 19.6, and 20.6° 2θ.

12 . The pharmaceutical composition of claim 11 , further comprising a capsule.